Total Payments
$18,955
2022 Payments
$119.23
Companies
11
Transactions
68
Medicare Patients
2,032
Medicare Billing
$235,813
Payment Breakdown by Category
Other$12,600 (66.5%)
Food & Beverage$2,510 (13.2%)
Consulting$1,750 (9.2%)
Travel$1,626 (8.6%)
Education$468.59 (2.5%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $12,600 | 7 | 66.5% |
| Food and Beverage | $2,510 | 45 | 13.2% |
| Consulting Fee | $1,750 | 1 | 9.2% |
| Travel and Lodging | $1,626 | 6 | 8.6% |
| Education | $468.59 | 9 | 2.5% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $15,206 | 37 | $0 (2019) |
| PUMA BIOTECHNOLOGY, INC. | $2,341 | 9 | $0 (2021) |
| Lilly USA, LLC | $392.88 | 4 | $0 (2021) |
| PFIZER INC. | $305.44 | 7 | $0 (2021) |
| Daiichi Sankyo Inc. | $244.17 | 3 | $0 (2021) |
| E.R. Squibb & Sons, L.L.C. | $150.32 | 2 | $0 (2022) |
| Incyte Corporation | $118.13 | 1 | $0 (2018) |
| AstraZeneca Pharmaceuticals LP | $92.89 | 2 | $0 (2022) |
| Exelixis Inc. | $75.00 | 1 | $0 (2017) |
| Merck Sharp & Dohme LLC | $17.14 | 1 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2022 | $119.23 | 3 | AstraZeneca Pharmaceuticals LP ($73.88) |
| 2021 | $691.64 | 10 | Lilly USA, LLC ($392.88) |
| 2020 | $224.79 | 2 | Daiichi Sankyo Inc. ($117.14) |
| 2019 | $6,770 | 14 | Novartis Pharmaceuticals Corporation ($6,621) |
| 2018 | $2,793 | 15 | Puma Biotechnology, Inc. ($2,094) |
| 2017 | $8,357 | 24 | Novartis Pharmaceuticals Corporation ($8,034) |
All Payment Transactions
68 individual payment records from CMS Open Payments — Page 1 of 3
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 09/01/2022 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $28.21 | General |
| Category: Oncology | ||||||
| 07/20/2022 | AstraZeneca Pharmaceuticals LP | CALQUENCE (Drug) | Food and Beverage | In-kind items and services | $73.88 | General |
| Category: Oncology | ||||||
| 05/12/2022 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $17.14 | General |
| Category: ONCOLOGY | ||||||
| 12/22/2021 | Daiichi Sankyo Inc. | INJECTAFER (Drug) | Food and Beverage | In-kind items and services | $14.90 | General |
| Category: Iron Deficiency Anemia | ||||||
| 10/11/2021 | AstraZeneca Pharmaceuticals LP | LYNPARZA (Drug) | Education | In-kind items and services | $19.01 | General |
| Category: Oncology | ||||||
| 09/28/2021 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $112.13 | General |
| Category: ONCOLOGY | ||||||
| 08/19/2021 | PFIZER INC. | ELIQUIS (Drug) | Food and Beverage | In-kind items and services | $15.80 | General |
| Category: CARDIOVASCULAR;METABOLIC DISEASE | ||||||
| 07/14/2021 | PUMA BIOTECHNOLOGY, INC. | NERLYNX (Drug) | Food and Beverage | In-kind items and services | $125.00 | General |
| Category: ONCOLOGY | ||||||
| 06/01/2021 | Gilead Sciences, Inc. | — | Education | In-kind items and services | $11.92 | General |
| 05/21/2021 | Lilly USA, LLC | — | Education | In-kind items and services | $120.46 | General |
| 05/21/2021 | Lilly USA, LLC | — | Education | In-kind items and services | $104.63 | General |
| 05/21/2021 | Lilly USA, LLC | — | Education | In-kind items and services | $104.63 | General |
| 05/21/2021 | Lilly USA, LLC | — | Education | In-kind items and services | $63.16 | General |
| 12/07/2020 | Puma Biotechnology, Inc. | NERLYNX (Drug) | Food and Beverage | In-kind items and services | $107.65 | General |
| Category: ONCOLOGY | ||||||
| 02/20/2020 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $117.14 | General |
| Category: Oncology | ||||||
| 12/18/2019 | Puma Biotechnology, Inc. | Nerlynx (Drug) | Education | In-kind items and services | $15.00 | General |
| Category: Oncology | ||||||
| 12/12/2019 | PFIZER INC. | IBRANCE (Drug) | Food and Beverage | In-kind items and services | $8.98 | General |
| Category: ONCOLOGY | ||||||
| 11/20/2019 | Novartis Pharmaceuticals Corporation | MEKINIST (Drug), TAFINLAR | Food and Beverage | In-kind items and services | $12.05 | General |
| Category: ONCOLOGY | ||||||
| 10/02/2019 | Novartis Pharmaceuticals Corporation | KISQALI (Drug), PIQRAY | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,500.00 | General |
| Category: ONCOLOGY | ||||||
| 10/02/2019 | Novartis Pharmaceuticals Corporation | KISQALI (Drug), PIQRAY | Food and Beverage | In-kind items and services | $112.08 | General |
| Category: ONCOLOGY | ||||||
| 08/20/2019 | Novartis Pharmaceuticals Corporation | MEKINIST (Drug), TAFINLAR | Food and Beverage | In-kind items and services | $9.17 | General |
| Category: ONCOLOGY | ||||||
| 07/25/2019 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $600.00 | General |
| Category: ONCOLOGY | ||||||
| 06/13/2019 | Novartis Pharmaceuticals Corporation | MEKINIST (Drug), TAFINLAR | Food and Beverage | In-kind items and services | $4.73 | General |
| Category: ONCOLOGY | ||||||
| 06/12/2019 | PFIZER INC. | TALZENNA (Drug) | Food and Beverage | In-kind items and services | $125.00 | General |
| Category: ONCOLOGY | ||||||
| 04/04/2019 | Novartis Pharmaceuticals Corporation | MEKINIST (Drug), TAFINLAR | Food and Beverage | In-kind items and services | $3.93 | General |
| Category: ONCOLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 2 | 130 | 140 | $23,694 | $9,949 |
| 2022 | 6 | 565 | 766 | $146,391 | $68,918 |
| 2021 | 6 | 627 | 857 | $167,663 | $76,890 |
| 2020 | 8 | 710 | 998 | $206,290 | $80,056 |
Total Patients
2,032
Total Services
2,761
Medicare Billing
$235,813
Procedure Codes
22
All Medicare Procedures & Services
22 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 76 | 86 | $14,848 | $7,055 | 47.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 54 | 54 | $8,846 | $2,894 | 32.7% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 202 | 331 | $56,802 | $35,005 | 61.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 237 | 260 | $40,812 | $16,649 | 40.8% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 52 | 52 | $16,084 | $6,752 | 42.0% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 36 | 79 | $19,355 | $6,233 | 32.2% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 25 | 25 | $11,875 | $3,894 | 32.8% |
| G2212 | Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Office | 2022 | 13 | 19 | $1,463 | $384.68 | 26.3% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 192 | 329 | $55,478 | $33,508 | 60.4% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 278 | 308 | $48,070 | $20,695 | 43.1% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 47 | 107 | $26,671 | $8,808 | 33.0% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 49 | 49 | $15,026 | $6,385 | 42.5% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 38 | 40 | $19,320 | $6,384 | 33.0% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 23 | 24 | $3,098 | $1,109 | 35.8% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Office | 2020 | 209 | 368 | $59,370 | $31,071 | 52.3% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 254 | 289 | $44,224 | $14,641 | 33.1% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 57 | 124 | $27,420 | $10,475 | 38.2% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2020 | 47 | 48 | $20,400 | $7,869 | 38.6% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Office | 2020 | 47 | 47 | $12,965 | $6,115 | 47.2% |
| 99354 | Prolonged office or other outpatient service first hour | Office | 2020 | 50 | 61 | $25,315 | $6,075 | 24.0% |
| 99358 | Prolonged patient service without direct patient contact first hour | Office | 2020 | 26 | 35 | $13,300 | $2,760 | 20.8% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 20 | 26 | $3,296 | $1,050 | 31.9% |
About Dr. Maureen Sheehan, M.D
Dr. Maureen Sheehan, M.D is a Hematology & Oncology healthcare provider based in Kansas City, Missouri. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 02/01/2006. The National Provider Identifier (NPI) number assigned to this provider is 1235100637.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Maureen Sheehan, M.D has received a total of $18,955 in payments from pharmaceutical and medical device companies, with $119.23 received in 2022. These payments were reported across 68 transactions from 11 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($12,600).
As a Medicare-enrolled provider, Sheehan has provided services to 2,032 Medicare beneficiaries, totaling 2,761 services with total Medicare billing of $235,813. Data is available for 4 years (2020–2023), covering 22 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Other Specialties Hematology & Oncology
- Location Kansas City, MO
- Active Since 02/01/2006
- Last Updated 03/08/2017
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1235100637
Products in Payments
- KISQALI (Drug) $14,760
- Nerlynx (Drug) $2,109
- NERLYNX (Drug) $232.65
- Enhertu (Drug) $229.27
- IBRANCE (Drug) $164.64
- TALZENNA (Drug) $125.00
- JAKAFI (Drug) $118.13
- Cabometyx (Drug) $75.00
- CALQUENCE (Drug) $73.88
- MEKINIST (Drug) $29.88
- OPDIVO (Biological) $28.21
- LYNPARZA (Drug) $19.01
- KEYTRUDA (Biological) $17.14
- ELIQUIS (Drug) $15.80
- INJECTAFER (Drug) $14.90
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Kansas City
Dr. Suman Kambhampati, Md, MD
Hematology & Oncology — Payments: $281,918
Hematology & Oncology $281,918
Dr. Shahzad Raza, Md, MD
Hematology & Oncology — Payments: $184,113
Hematology & Oncology $184,113
Joseph Mcguirk, D.o, D.O
Hematology & Oncology — Payments: $129,700
Hematology & Oncology $129,700
Dr. Stephanie Graff, M.d, M.D
Hematology & Oncology — Payments: $120,151
Hematology & Oncology $120,151
Jaswinder Singh, Md, MD
Hematology & Oncology — Payments: $86,702
Hematology & Oncology $86,702
Dr. Tara Lin, Md, MD
Hematology & Oncology — Payments: $24,114
Hematology & Oncology $24,114